Daudi

Manufactured by Leibniz Institute DSMZ

Sourced in Germany

Daudi is a laboratory equipment produced by the Leibniz Institute DSMZ. It is a cell line derived from a Burkitt's lymphoma. The core function of Daudi is to serve as a model system for the study of human B-cell biology and lymphoma.

Automatically generated - may contain errors

Lab products found in correlation

6 protocols using daudi

Cell Culture Protocol for Lymphoma Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human cell lines, BL-41, GRANTA-519, DAUDI, REC-1, SU-DHL-4, U2932, SC-1, MINO, K562, and MAVER-1 were obtained from DSMZ. J76 was a kind gift from M. Heemskerk (Leiden University Medical Center, the Netherlands). EBV-transformed B cell lines were generated in house. The cells were cultured in RPMI 1640 (PAA, Paschung, Austria) and supplemented with 10% fetal calf serum (FCS, PAA) and 50 μg/ml Gentamycin (Thermo Fischer, Oslo, Norway). The Phoenix-AMPHO (CRL-3213) cell line was purchased from ATCC (Manassas, VA, USA) and was maintained in Dulbecco's modified Eagle's medium (Sigma-Aldrich, Oslo, Norway) supplemented with 10% FCS and 50 μg/ml Gentamycin.

Köksal H., Dillard P., Juzeniene A., Kvalheim G., Smeland E.B., Myklebust J.H., Inderberg E.M, & Wälchli S. (2020). Combinatorial CAR design improves target restriction. The Journal of Biological Chemistry, 296, 100116.

+ Open protocol

+ Expand

Cell Line Cultivation and Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Raji cell line was purchased from ATCC. KMS-12-BM, NCI-H929, MOLP8 and Daudi were obtained from DSMZ. Raji-KO and NCI-H929 KO cell lines have been generated in-house using CRISPR/CAS9 technology and clones isolated using Fluorescence-Activated-Cell sorter (FACS). All cell lines were cultured in RPMI 1640 medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS,Gibco), 2 mM l-glutamine (Gibco), 1% non-essential amino acids (Gibco) and 1 mM sodium pyruvate (Gibco) and maintained at 37 °C under an atmosphere containing 5% CO₂. Mycoplasma and short tandem repeat (STR) analysis was routinely evaluated by Microsynth (Balgach, Switzerland) passage 5 and passage 15 according to Microsynth guidelines. No commonly misidentified cell lines were used (according to ICLAC register version 10).

Grandclément C., Estoppey C., Dheilly E., Panagopoulou M., Monney T., Dreyfus C., Loyau J., Labanca V., Drake A., De Angelis S., Rubod A., Frei J., Caro L.N., Blein S., Martini E., Chimen M., Matthes T., Kaya Z., Edwards C.M., Edwards J.R., Menoret E., Kervoelen C., Pellat-Deceunynck C., Moreau P., Mbow M.L., Srivastava A., Dyson M.R., Zhukovsky E.A., Perro M, & Sammicheli S. (2024). Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma. Nature Communications, 15, 2054.

+ Open protocol

+ Expand

Characterization of Burkitt Lymphoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human BL cell lines RAMOS, DG-75, RAJI, BJAB and DAUDI were obtained from the German Collection of Microorganisms and Cell cultures (DSMZ, Braunschweig, Germany) and BL-2, BL-30, Seraphine, BL-60, BL-70 and Salina cells were kindly provided by T. Oellerich, Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Germany. All cell lines were authenticated by STR profiling and continuously monitored for mycoplasma contamination. Cells were cultured in RPMI 1640 (Life Technologies), supplemented with 10% or 20% fetal calf serum (FCS) and 1% penicillin/streptomycin (Invitrogen). The bivalent Smac mimetic BV6 was kindly provided by Genentech. The broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk) was purchased from Bachem, Necrosulfonamide (NSA) from Toronto Research Chemicals Inc., GSK’872 and Necrostatin-1s (Nec-1s) from Merck and Dabrafenib from Selleck Chemicals. Recombinant human TRAIL was obtained from R&D Systems, human recombinant TNFα from PeproTech and human multimeric FASL from AdipoGen. Doxycycline hydrochloride (DOX) was purchased from Sigma-Aldrich. LCL-161 was purchased from Novartis and AT-406, Birinapant and SGI-110 (Guadecitabine) were obtained from Selleck Chemicals. All other chemicals were purchased from Sigma-Aldrich or Carl Roth unless indicated otherwise.

Koch A., Jeiler B., Roedig J., van Wijk S.J., Dolgikh N, & Fulda S. (2021). Smac mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt's lymphoma cell lines. Neoplasia (New York, N.Y.), 23(5), 539-550.

+ Open protocol

+ Expand

Cell Culture of Lymphoma Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Jeko-1, Mino, Daudi, U-2932, Raji, and Ramos cell lines were obtained from the German Collection of Microorganisms and Cell Cultures or the American Type Culture Collection and cultured in standard medium.

Her J.H., Pretscher D., Patra-Kneuer M., Schanzer J., Cho S.Y., Hwang Y.K., Hoeres T., Boxhammer R., Heitmueller C., Wilhelm M., Steidl S, & Endell J. (2022). Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunology, Immunotherapy, 71(11), 2829-2836.

+ Open protocol

+ Expand

Cell Line Maintenance and Validation

Check if the same lab product or an alternative is used in the 5 most similar protocols

U698M, Daudi, 380, Nalm6, K562, and MeC2 cell lines used in this study were purchased from German Collection of Microorganisms and Cell Cultures (DSMZ). The culture condition and cell maintaining for each cell line were according to official guidelines of the DSMZ. All cell lines were used in logarithmic growth phase and mycoplasma were excluded by polymerase chain reaction (PCR).

Yang M., Wang L., Ni M., Neuber B., Wang S., Gong W., Sauer T., Sellner L., Schubert M.L., Hückelhoven-Krauss A., Hong J., Zhu L., Kleist C., Eckstein V., Müller-Tidow C., Dreger P., Schmitt M, & Schmitt A. (2020). Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. Frontiers in Immunology, 11, 608167.

+ Open protocol

+ Expand

Culturing Cell Lines for Myeloma Research

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

L-363, U-266, Daudi, Raji and CHO-K1 cells were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ; cat. no. ACC 49, ACC 9, ACC 78, ACC 110), whereas CEM were purchased from the American Type Culture Collection (ATCC; cat. no. CCL-119). L-363, U-266, Raji, Daudi and CEM cells were cultured in RPMI 1640 GlutaMAX medium containing 10% FCS, 1% penicillin and streptomycin (R10+; all Thermo Fisher Scientific; cat. no. 72400-021, 10270-106, 15140-122). CHO-K1 cells were cultured in DMEM medium containing 10% FCS, 1% penicillin and streptomycin (D10+; all Thermo Fisher Scientific; cat. no. 41965-039, 10270-106, 15140-122). HUVEC and CHO-S cells were ordered from Lonza (cat. no. CC-2519) and Thermo Fisher Scientific (cat. no. R800-07), respectively, and cultured according to manufacturer’s instructions. The human plasma cell line INA-6 was cultured in RPMI 1640 GlutaMAX medium containing 20% FCS, 1% penicillin and streptomycin supplemented with 10 ng/ml recombinant human IL-6 (Thermo Fisher Scientific; cat. no. PHC0061) (25 (link)). Stable transfected CHO-K1 cells expressing myeloma antigens were generated and cultured as described (23 (link)).

Krohn S., Boje A.S., Gehlert C.L., Lutz S., Darzentas N., Knecht H., Herrmann D., Brüggemann M., Scheidig A.J., Weisel K., Gramatzki M., Peipp M, & Klausz K. (2022). Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display. Frontiers in Immunology, 13, 908093.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!